Criterion Capital Advisors LLC Acquires 70 Shares of Danaher Co. (NYSE:DHR)

Criterion Capital Advisors LLC grew its holdings in Danaher Co. (NYSE:DHR) by 2.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,044 shares of the conglomerate’s stock after purchasing an additional 70 shares during the quarter. Criterion Capital Advisors LLC’s holdings in Danaher were worth $760,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Mather Group LLC. grew its position in Danaher by 98.1% during the 3rd quarter. Mather Group LLC. now owns 3,175 shares of the conglomerate’s stock worth $788,000 after purchasing an additional 1,572 shares during the last quarter. Bamco Inc. NY grew its holdings in shares of Danaher by 30.3% during the third quarter. Bamco Inc. NY now owns 21,743 shares of the conglomerate’s stock valued at $5,394,000 after buying an additional 5,060 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Danaher by 328.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 25,076 shares of the conglomerate’s stock valued at $6,221,000 after acquiring an additional 19,217 shares during the period. Morningstar Investment Services LLC purchased a new position in Danaher in the 3rd quarter worth $281,000. Finally, Cape Cod Five Cents Savings Bank grew its stake in Danaher by 108.6% during the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 3,140 shares of the conglomerate’s stock valued at $779,000 after purchasing an additional 1,635 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR traded down $1.64 during mid-day trading on Friday, hitting $249.85. The stock had a trading volume of 4,638,276 shares, compared to its average volume of 3,371,169. The company has a 50 day simple moving average of $255.96 and a 200 day simple moving average of $246.43. The company has a market cap of $185.06 billion, a price-to-earnings ratio of 42.35, a P/E/G ratio of 3.85 and a beta of 0.85. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $269.11. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.36 earnings per share. Equities analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CFO Matthew Mcgrew sold 46,377 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $7,441,441.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the sale, the chief executive officer now owns 106,990 shares in the company, valued at approximately $28,352,350. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 148,783 shares of company stock worth $37,536,717. 11.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DHR shares. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Barclays upped their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Jefferies Financial Group initiated coverage on shares of Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Robert W. Baird upped their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Finally, StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $269.29.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.